Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Non-small-cell lung carcinoma | D002289 | — | — | — | 1 | — | — | — | 1 |
Lung neoplasms | D008175 | HP_0100526 | C34.90 | — | 1 | — | — | — | 1 |
Recurrence | D012008 | — | — | — | 1 | — | — | — | 1 |
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | 1 | — | — | — | 1 |
Ovarian epithelial carcinoma | D000077216 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | 8 | — | — | — | — | 8 |
Paraneoplastic syndromes | D010257 | — | — | 1 | — | — | — | — | 1 |
Drug common name | Ombrabulin |
INN | ombrabulin |
Description | Ombrabulin was an experimental drug candidate discovered by Ajinomoto and further developed by Sanofi-Aventis. Ombrabulin is a combretastatin A-4 derivative that exerts its antitumor effect by disrupting the formation of blood vessels needed for tumor growth.
|
Classification | Small molecule |
Drug class | antineoplastics (mitotic inhibitors; tubulin binders) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO |
PDB | — |
CAS-ID | 181816-48-8 |
RxCUI | — |
ChEMBL ID | CHEMBL572284 |
ChEBI ID | — |
PubChem CID | 6918405 |
DrugBank | — |
UNII ID | 82JB1524Q6 (ChemIDplus, GSRS) |